The drug, which will be marketed under the brand name Covifor and Cipremi
WEB DESK
India’s top drug regulatory body, the Central Drugs Standard Control Organisation’s (CDSCO) has reportedly given its approval to Hetero Labs and Cipla Ltd to manufacture and market their generic version of Gilead Sciences Inc’s experimental COVID-19 treatment remdesivir.
The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100-milligram dose, Hetero said.
India’s Cipla said its generic version of remdesivir will be called Cipremi.
Gilead Sciences Inc signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its COVID-19 treatment.
The pacts allow Jubilant Life Sciences Ltd, Cipla, Hetero Labs, Mylan NV, and Ferozsons Laboratories Ltd to make and sell the drug in 127 countries.
Indian drugmaker Zydus Cadila said last week it signed a non-exclusive licensing pact with Gilead Sciences to manufacture and market remdesivir.